934831-81-9

Upstream product

• 934831-80-8 (+)-(1S,2R)-2-(hydroxy)-5-cyclohexenecarboxylic acid (N-methoxy-N-methyl)amide 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 2100-17-6 4-pentenal 
• 934831-73-9 (+)-(2S)-N-[(2S,3R)-2-(ethenyl)-3-(hydroxy)-6-heptenoyl]bornane-10,2-sultam 
• 934831-74-0 (+)-(2S)-N-[(1R,2S)-1-hydroxy-3-cyclohexene-2-carbonyl]bornane-10,2-sultam 
• 934831-75-1 (+)-(1S,2R)-2-hydroxy-5-cyclohexenecarboxylic acid 

Downstream Products

• 934831-83-1 (-)-(3aS,4S,5R,7aR)-5-(((tert-butyldiphenyl)silyl)oxy)-2,2-dimethylhexahydro-[1,3]benzodioxol-4-carboxylic acid (N-methoxy-N-methyl)amide 
• 934831-82-0 (-)-(1S,2S,3R,6R)-2,3-(dihydroxy)-6-(((tert-butyldiphenyl)silyl)oxy)cyclohexane-carboxylic acid (N-methoxy-N-methyl)amide 

Relevant academic research and scientific papers

Enantioselective synthesis of a potential key intermediate for the total synthesis of fumagillin

Key intermediate, 7, of a projected total synthesis of the anti-angiogenesis compound Fumagillin 1 and the semi-synthetic analogue TNP-470 2, has been prepared in enantiomerically pure form by employing an early nucleophilic addition ring closure [NARC] s